BAG3 and breast carcinoma: The compounds called carbamimidamido-2-[2-(phenylformamido) acetamido]pentanoicacid (ZN02516109) and (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) acid (ZINC72169376) which bound 4 pharmacore points (Supplementary Figure 10) at the HSP70-BAG3 interface were tested in addition to YM-1 a compound reported to disrupt the BAG3:HSP70 interaction in breast cancer cell lines [13].